



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

8 October 2020
EMA/535780/2020
Human Medicines Division

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use October 2020

This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation. It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP). For generic and biosimilar medicines, it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area.

This list only includes information for medicines whose applications have been validated at the time the report was compiled. The information in this report was compiled on 7 October 2020.

Information on designated orphan medicines that are being assessed for marketing authorisation is also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

Information in bold corresponds to new entries in the monthly list.

Entries are removed from this list once the medicine has received a positive or negative opinion from the CHMP or when the applicant has withdrawn the application. The Agency publishes information on these opinions and withdrawn applications on its website.

Information on CHMP opinions is also published in the monthly CHMP highlights.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000

An agency of the European Union



Non-orphan medicinal products

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ⁱ
Arachis hypogaea allergens	Allergens
Autologous human chondrocytes in vitro expanded ^{iv}	Other medicines for disorders of the musculo-skeletal system
Azacitidine	Antineoplastic medicines
Baloxavir marboxil	Antivirals for systemic use
Bevacizumab	Ophthalmologicals
Bimekizumab	Immunosuppressants
Budesonide / glycopyrronium (bromide) / formoterol (fumarate dihydrate)	Nasal medicines
Cabotegravir (sodium)	Antivirals for systemic use
Cenobamate	Antiepileptics
Dostarlimab	Antineoplastic medicines
Estetrol (monohydrate) / drospirenone	Sex hormones and modulators of the genital system
Evinacumab ⁱⁱ	Lipid modifying medicines
Fluticasone (propionate) / Salmeterol (xinafoate)	Medicines for obstructive airway diseases
Fostemsavir (trometamol)	Antivirals for systemic use
Hepatitis B surface antigen	Vaccines
Icosapent (ethyl)	Lipid modifying medicines
Inclisiran	Lipid modifying medicines
Istradefylline	Anti-parkinson medicines
Netarsudil (mesilate) / latanoprost	Ophthalmologicals
Obeticholic (acid)	Bile and liver therapy
Ofatumumab	Immunosuppressants
Pertuzumab / trastuzumab	Antineoplastic medicines
Pitolisant (hydrochloride)	Other nervous system medicines
Ponesimod	Immunosuppressants
Pralsetinib	Antineoplastic medicines
Relugolix / estradiol (hemihydrate) / norethisterone (acetate)	Pituitary and hypothalamic hormones and analogues
Remimazolam (besilate)	Psycholeptics
Rilpivirine	Antivirals for systemic use

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ⁱ
Roxadustat	Antianemic medicines
Salmeterol (xinafoate) / fluticasone (propionate)	Medicines for obstructive airway diseases
Selpercatinib	Antineoplastic medicines
Sodium thiosulfate	Other therapeutic medicines
Tanezumab	Analgesics
Tirbanibulin (mesilate)	Antibiotics and chemotherapeutics for dermatological use
Tralokinumab	Other dermatological medicines
Trastuzumab (deruxtecan) ⁱⁱ	Antineoplastic medicines
Tucatinib	Antineoplastic medicines
Vericiguat	Cardiac therapy

ⁱ Based on the ATC therapeutic sub-group.

ⁱⁱ Under EMA's accelerated assessment programme of Article 14(9) of Regulation (EC) No 726/2004 .

ⁱⁱⁱ Submitted according to legal basis: Informed consent application (Article 10c of Directive No 2001/83/EC).

^{iv} Medicine classified as advanced therapy medicinal product (ATMP).

Non-orphan generic and biosimilar medicinal products

International non-proprietary name / Common Name	Therapeutic area ⁱ	Total number of applications
Abiraterone	Endocrine therapy	3
Adalimumab	Immunosuppressants	2
Azathioprine	Immunosuppressants	1
Bevacizumab	Antineoplastic medicines	5
Dabigatran	Antithrombotic medicines	1
Dasatinib	Antineoplastic medicines	2
Dexamethasone ^{vi}	Corticosteroids for systemic use	1
Doxorubicin	Antineoplastic medicines	2
Glucagon	Pancreatic hormones	1
Icatibant	Other hematological medicines	1
Imatinib	Antineoplastic medicines	1
Insulin aspart	Medicines used in diabetes	1
Insulin human (rDNA)	Medicines used in diabetes	1
Ioflupane (123I)	Diagnostic radiopharmaceuticals	1

International non-proprietary name / Common Name	Therapeutic area ⁱ	Total number of applications
Lenalidomide	Immunosuppressants	4
Leuprorelin	Endocrine therapy	1
Pegfilgrastim	Immunostimulants	1
Ranibizumab	Ophthalmologicals	1
Risperidone	Psycholeptics	1
Rivaroxaban	Antithrombotic medicines	1
Sildenafil	Urologicals	1
Sitagliptin	Medicines used in diabetes	1
Sugammadex	Other therapeutic medicines	1
Sunitinib	Antineoplastic medicines	1
Teriparatide	Calcium homeostasis	1
Thiotepa	Antineoplastic medicines	1
Trastuzumab	Antineoplastic medicines	1

ⁱ Based on the ATC therapeutic sub-group.

^{vi} Accelerated timetable for COVID-19 related medicine.

Orphan medicinal products

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ⁱ
Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene ^{iv, v}	Other nervous system medicines
Autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated ^{iv}	Antineoplastic medicines
Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured ^{iv}	Antineoplastic medicines
Avalglucosidase alfa	Other alimentary tract and metabolism products
Berotrastat (hydrochloride)	Other hematological medicines
Duvelisib	Antineoplastic medicines
Eflornithine (hydrochloride) / sulindac	Antineoplastic medicines
Eladocagene exuparvovec ^{iv}	Other nervous system medicines

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ⁱ
Elivaldogene autotemcel ^{ii, iv}	Other nervous system medicines
Fedratinib (dihydrochloride monohydrate)	Antineoplastic medicines
Fenfluramine	Antiepileptics
Glucarpidase	Other therapeutic medicines
Hydrocortisone	Corticosteroids for systemic use
Idebenone (titanium dioxide)	Psychoanaleptics
Idecabtagene vicleucel ^{ii, iv}	Antineoplastic medicines
Ivosidenib	Antineoplastic medicines
Lisocabtagene maraleucel ^{ii, iv}	Antineoplastic medicines
Lonafarnib	Other alimentary tract and metabolism products
Lumasiran (sodium) ⁱⁱ	Other alimentary tract and metabolism products
Moxetumomab pasudotox	Antineoplastic medicines
Pegcetacoplan	Immunosuppressants
Pemigatinib	Antineoplastic medicines
Potassium citrate / potassium hydrogen carbonate	Mineral supplements
Ripretinib	Antineoplastic medicines
Risdiplam ⁱⁱ	Other medicines for disorders of the musculo-skeletal system
Satralizumab	Immunosuppressants
Selinexor	Antineoplastic medicines
Selumetinib (sulfate)	Antineoplastic medicines
Setmelanotide ⁱⁱ	Antiobesity medicines
Somapacitan	Pituitary and hypothalamic hormones and analogues
Tafasitamab	Antineoplastic medicines
Valoctocogene roxaparvovec ^{ii, iv}	Antihemorrhagics
Vosoritide	Medicines for bone diseases
Zanubrutinib	Antineoplastic medicines

ⁱ Based on the ATC therapeutic sub-group.

ⁱⁱ Under EMA's accelerated assessment programme cf. Article 14(9) of Regulation (EC) No 726/2004.

ⁱⁱⁱ Submitted according to legal basis: Informed consent application (Article 10c of Directive No 2001/83/EC).

^{iv} Medicine classified as advanced therapy medicinal product (ATMP).

^v Product no longer being reviewed under EMA's accelerated assessment programme.